#JPM26: Day 3 at the JP Morgan Healthcare Conference

ENDPOINTS / endpoints - It’s Wednesday at the JP Morgan Healthcare Conference, and as the sessions wind down, we’ll be keeping an eye on presentations from WuXi AppTec and AbbVie. Yesterday afternoon, our Executive Editor Drew Armstrong spoke with ...

AI Summary: At the JP Morgan Healthcare Conference 2026, top industry leaders unveiled transformative developments—from embedding AI into EHR systems to discussions on GLP‐1 compounding innovations and strategic Q&A sessions with leading pharma CEOs. The event provided a broad overview of emerging trends in healthcare technology and innovation.

Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access

Ella Jeffries / beckershospitalreview - Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition. The lawsuit, filed i…

AI Summary: A compounding pharmacy has taken legal aim at industry giants Eli Lilly and Novo Nordisk, alleging an anti‑competitive scheme designed to restrict access to their blockbuster GLP‑1 therapies. The lawsuit puts the pharmaceutical titans on the defensive as antitrust concerns mix with therapeutic access debates.

FDA moves to remove suicide warnings from GLP-1 weight loss drugs

medicalxpress - Federal health regulators say popular weight loss drugs like Wegovy and Zepbound do not increase the risk of suicidal thoughts, and they have asked drugmakers to remove those warnings from medication labels.

AI Summary: In a surprising twist, the FDA has decided that the long‐rumored risk of suicidal ideation on popular GLP‑1 weight‐loss drugs may have been overblown. Regulators have now asked drugmakers – including Lilly and Novo Nordisk – to scrub these warnings from product labels, a move that is sure to spark both relief and raised eyebrows among critics.

New US diet guidelines push whole foods, meat and dairy

medicalxpress - The federal government has released new dietary guidelines that shift how Americans are urged to eat.

AI Summary: The federal government has unveiled a major revision in its dietary guidelines—urging Americans to favor whole foods such as lean meats, dairy and protein sources while cutting ultraprocessed items. This unexpected pivot in nutritional policy is sparking conversations about what “healthy eating” will really mean moving forward.

UK starts ban on junk food ads on daytime TV and online

medicalxpress - New regulations come into force Monday in Britain banning daytime TV and online adverts for so-called junk foods, in what the government calls a "world-leading action" to tackle childhood obesity.

AI Summary: British regulators have implemented new rules banning junk food advertisements on daytime TV and online platforms. The measures—targeting products like soft drinks, chocolate, pizza, and ice cream—are part of a government drive to curb unhealthy food marketing and protect public health, especially among younger audiences.

Foods with healthy-sounding buzzwords could be hiding added sugar in plain sight

medicalxpress - Many consumers feel pride in avoiding the glazed pastries in the supermarket and instead opting for "all natural" granola that comes packed with extra protein. Same goes for low-fat yogurts "made with real fruit," "organic" plant-based milks and bottled "…

AI Summary: Investigative posts reveal that foods flaunting “all‐natural” or “healthy” buzzwords can secretly pack in a surprising amount of added sugars, leaving consumers to wonder if their guilt‐free choices are anything but sweet. A reminder that not every label is as wholesome as it sounds.

Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss

Frank Vinluan / medcitynews - Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January.…

AI Summary: The FDA has given its nod to Novo Nordisk’s oral GLP‑1 receptor agonist for chronic weight management – a historic first for an anti‑obesity pill. The approval offers patients a non‑injectable alternative, potentially transforming obesity care in a market hungry for innovation.

Novo submits high-dose Wegovy for FDA approval using voucher

Max Bayer / endpoints - Novo Nordisk submitted a higher dose of its obesity drug Wegovy for FDA approval and is using a recently-won voucher to expedite the review. The company said Wednesday that it submitted ...

AI Summary: Novo Nordisk has formally submitted its application to the FDA to approve a higher-dose formulation of its flagship obesity drug, Wegovy. Leveraging a recently secured priority voucher, the filing is set to potentially expand treatment options for weight management as the review process begins.

Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials

Ella Jeffries / beckershospitalreview - Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo…

AI Summary: Novo Nordisk’s much‑talked‑about GLP‑1 drug, famed for its weight‐loss benefits, has hit an unexpected wall in Alzheimer’s trials. In two separate reports – one on the standard injectable and another on a pill form – semaglutide showed no statistically significant impact on slowing brain decline. Who knew obesity meds couldn’t multitask?

Novo Nordisk rolls out lower prices for Ozempic and Wegovy

medicalxpress - People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

AI Summary: In a bid to ease the financial burden on self‐pay patients, Novo Nordisk has unveiled deep price cuts for its flagship GLP-1 drugs, Ozempic and Wegovy. The new pricing strategy comes amid intensifying market pressures and aims to broaden access to these critical therapies for weight management and type 2 diabetes.

Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera

Frank Vinluan / medcitynews - Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favo…

AI Summary: In a dramatic showdown over obesity biotech firm Metsera, Pfizer’s up-to-$10B cash offer edged out Novo Nordisk’s bid. The fiercely competitive deal highlights the high stakes and intense market focus on innovative therapeutics in obesity management.

Pfizer poised to buy Metsera in $10 bn deal after bidding war

medicalxpress - Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's board and Danish challenger Novo Nordisk called a halt to a back-and-forth bidding war.

AI Summary: In a dramatic bidding war for a promising biotech startup, Pfizer’s improved $10 billion offer prevailed—until Novo Nordisk raised its bid yet again. This high-stakes takeover tussle underscores the fierce competition and strategic importance of emerging therapies.

What Trump’s New Drug Pricing Deal Means for People With Obesity

Rebecca Robbins, Dani Blum and Margot Sanger-Katz / nytimes - The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

AI Summary: In a bold move to tackle the obesity crisis, the Trump administration has brokered agreements with industry giants such as Eli Lilly and Novo Nordisk to slash weight-loss drug prices. The deals, promising reductions as steep as $149 a month, have sparked both applause and debate over the future of drug pricing in America.